Gliomas News

This RSS feed URL is deprecated


This RSS feed URL is deprecated, please update. New URLs can be found in the footers at https://news.google.com/news

Immunotherapy Techniques Are Being Explored in Gliomas - Curetoday.com



Curetoday.com
 
Immunotherapy Techniques Are Being Explored in Gliomas 
Curetoday.com
Solutions could involve finding ways to revive these T cells or targeting different T cells, he said. Gliomas are characterized by the presence of many myeloid cells, which cause immunosuppression. This could be a barrier to immunotherapy, but finding ...

and more » 


Innovative technique makes low-grade gliomas visible - News-Medical.net



News-Medical.net
 
Innovative technique makes low-grade gliomas visible 
News-Medical.net
Gliomas are a type of brain tumor characterized by a poor prognosis. In order to improve this prognosis, as much of the tumor as possible must be removed safely during the neurosurgical operation. However, especially in the case of slow-growing, low ...

 


Remove Obstacles to Palliative Care for Patients With High-Grade Gliomas - Curetoday.com



Curetoday.com
 
Remove Obstacles to Palliative Care for Patients With High-Grade Gliomas 
Curetoday.com
Quality-of-life care has benefits from the outset for these patients, but because some might confuse it with end-of-life support, neuro-oncologists may be hesitant about introducing it. BY Beth Fand Incollingo. PUBLISHED November 20, 2017. There's a ...

and more » 


Innovative probe visualises tumours - Drug Target Review



Drug Target Review
 
Innovative probe visualises tumours 
Drug Target Review
In a joint project, MedUni Vienna, the University of California in San Francisco and the Dartmouth-Hitchcock Medical Center (both USA) have trialled a technique designed to make low-grade gliomas visible. The technique involved using an innovative ...

 


Deciphera Pharmaceuticals (DCPH) Announces Data from Ongoing Phase 1 Clinical Study of DCC-2618 - StreetInsider.com



Deciphera Pharmaceuticals (DCPH) Announces Data from Ongoing Phase 1 Clinical Study of DCC-2618 
StreetInsider.com
Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) today announced the presentation of data from its ongoing Phase 1 clinical trial of DCC-2618, the Company's pan-KIT and PDGFR? inhibitor, in patients with malignant gliomas. The data were presented as a ...
Deciphera Pharma's lead candidate shows positive effect in early-stage glioma study; shares ahead 6% Seeking Alpha

all 9 news articles » 


Malignant Glioma Market Report 2016 ? 2022: By Therapy, Distribution channel, Regional Outlook and Key Player - satPRnews (press release)



Malignant Glioma Market Report 2016 ? 2022: By Therapy, Distribution channel, Regional Outlook and Key Player 
satPRnews (press release)
Malignant glioma's are one of the common sub-type of primary brain tumors which are highly invasive, aggressive and neurologically destructive tumors among the deadliest human cancers. Gliomas account for around 45% of primary brain tumors where ...

 


New Immunotherapy for Deadly Childhood Brain Cancer Targets Novel 'Neoantigen' - UCSF News Services



UCSF News Services
 
New Immunotherapy for Deadly Childhood Brain Cancer Targets Novel 'Neoantigen' 
UCSF News Services
Children with an extremely deadly form of brain cancer might benefit from a new treatment that aims to direct an immune response against a mutant form of a protein found exclusively on cancer cells, according to a new study led by UC San Francisco ...
A novel immuno-oncology approach to treating a rare childhood brain cancer FierceBiotech

all 2 news articles » 


New treatment aims to target abnormally shaped protein in deadly ... - News-Medical.net



New treatment aims to target abnormally shaped protein in deadly ... 
News-Medical.net
Children with an extremely deadly form of brain cancer might benefit from a new treatment that aims to direct an immune response against an abnormally shaped protein found exclusively on cancer cells, according to a new study led by UC San Francisco ...

and more » 


Avastin Fully Approved For Most Aggressive Form Of Brain Cancer - Pharmaceutical Processing



Curetoday.com
 
Avastin Fully Approved For Most Aggressive Form Of Brain Cancer 
Pharmaceutical Processing
The U.S. Food and Drug Administration (FDA) has granted full approval for Genentech's Avastin (bevacizumab) for the treatment of adults with glioblastoma that progressed following prior therapy (referred to as recurrent disease). Avastin was previously ...
FDA Grants Bevacizumab Full Approval for Glioblastoma OncLive
FDA Grants Genentech's Avastin Full Approval for Most Aggressive Form of Brain Cancer Business Wire (press release)
FDA Fully Approves Avastin for Glioblastoma Treatment Curetoday.com

all 5 news articles » 


Princess-themed afternoon to benefit 3-year-old girl battling brain tumor - Joplin Globe



Joplin Globe
 
Princess-themed afternoon to benefit 3-year-old girl battling brain tumor 
Joplin Globe
"We were really thankful we had the time with Addy because this time last year, we were looking at her not surviving," said her grandmother, Ann Sooter, of Carthage. Addy was diagnosed one year ago, at the age of 2, with diffuse intrinsic pontine ...